According to the World Health Organization (WHO), Indonesia currently has the largest number worldwide of cumulative human cases and deaths due to avian influenza. The U.S. Centers for Disease Control and Prevention (CDC) reports that dengue fever, chikungunya fever, Japanese encephalitis, schistosomiasis, and leptospirosis are also endemic to this region.
WHO data indicate that, despite a relatively low expenditure on health for the region, Indonesia’s child mortality rate is low compared to its regional neighbors. The AIDS epidemic is concentrated mainly among injection drug users and sex workers in some regions, with a low rate of infection in the general population.
Currently, the National Institute for Allergy and Infectious Disease's (NIAID’s) funding in Indonesia supports research in HIV/AIDS, malaria, and influenza, including avian influenza. In the area of HIV/AIDS, Indonesia participates in the Asia and Australia region of the NIAID-supported International Epidemiologic Databases to Evaluate AIDS. NIAID also supports an extramural research project on anti-AIDS agents from marine organisms, which involves collaboration between a U.S. and Indonesian university. NIAID supports malaria-related research in Indonesia on nitric oxide and severe malaria. NIAID has had prior collaborations with the Naval Medical Research Unit (NAMRU) II in Jakarta, and is currently funding a NAMRU II project related to chloroquine resistance in Plasmodium falciparum.
NIAID supports the Southeast Asia Influenza Clinical Research Network (SEA ICRN), a multilateral, collaborative partnership of hospitals and institutions in Indonesia, Thailand, the United Kingdom, the United States, and Viet Nam. This partnership includes NIAID and international institutions, such as WHO, Oxford University, and the Wellcome Trust. There are currently three clinical sites in Indonesia that are part of SEA ICRN: Persahabatan Hospital, Professor Dr. Sulianti Saroso Hospital for Infectious Diseases, and Hasan Sadikin Hospital. These sites are involved in the therapeutic study of High-Dose versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized, Clinical Trial (SEA-001).
NIAID also has recently awarded a contract to St. Jude Children’s Research Hospital, Memphis, TN, to establish a Center of Excellence for Influenza Research and Surveillance to conduct basic influenza research activities and animal surveillance in Indonesia, in collaboration with Hong Kong/China and Thailand.
back to top
Last Updated October 15, 2012
Last Reviewed October 15, 2012